Back to today’s briefing

Story perspectives

AI and Quantum Tech Unite to Transform Drug Discovery

1/30/2025

42 4

Summary

Story summary

Acellera Therapeutics and Psivant Therapeutics have joined forces to revolutionize drug discovery through the power of AI and quantum simulations. By merging Acellera’s AceForce technology with Psivant’s QUAISAR platform, they aim to streamline small molecule screening. This groundbreaking initiative, backed by the European Regional Development Fund, seeks to fast-track the creation of innovative treatments for tough diseases.

History

Historical Context

Acellera Therapeutics and Psivant Therapeutics' collaboration mirrors past advancements in drug discovery, such as the 2016 merger of Celgene and Bristol-Myers Squibb, which aimed to enhance therapeutic development. Historically, biotechnology firms have leveraged technology to expedite drug discovery, reflecting a trend towards integrating computational methods and AI, similar to past innovations like high-throughput screening in the 1990s.

1 of 2

Story summary

Acellera Therapeutics and Psivant Therapeutics have joined forces to revolutionize drug discovery through the power of AI and quantum simulations. By merging Acellera’s AceForce technology with Psivant’s QUAISAR platform, they aim to streamline small molecule screening. This groundbreaking initiative, backed by the European Regional Development Fund, seeks to fast-track the creation of innovative treatments for tough diseases.

1 / 2